title: Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation--how effective and for how long?
abstract: Pneumocystis carinii pneumonia (PCP) is a common clinical problem in the setting of organ transplantation, particularly in heart-lung and lung allograft recipients. Without prophylactic measurements, the incidence of P carinii pneumonia can reach up to 88% of heart-lung transplant recipients. We conducted a retrospective analysis of the Stanford heart-lung and lung transplant experience in order to assess the efficacy of the prophylactic therapy and to try to define the duration of therapy necessary for prevention. During a 9-year period 82 heart-lung and 13 single-lung transplants were performed. Of the patients not on prophylaxis therapy 27% (13 patients) developed P carinii infection as compared with 0% of patients on trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis. The incidence of PCP infection peaked between 3 and 6 months posttransplantation. No case of infection was observed before the 7th week posttransplant. PCP was more common following induction immunosuppression with OKT3 as compared with RATG (P less than 0.05). All cases of infections later than one year posttransplant were associated with recent increase in the immunosuppression regimen with high-dose corticosteroids for treatment of acute or chronic (obliterative bronchiolitis) rejection. Although our study is retrospective and based on various immunosuppressive and diagnostic technique periods, it seems that TMP-SMX is highly effective in preventing PCP infections in heart-lung and lung transplant recipients. Twelve months of therapy is probably a sufficient length of therapy if immunosuppressive therapy is stable. However, whenever augmentation in the immunosuppression regimen is indicated, prophylactic therapy should promptly be restarted.
authors.affiliation: Department of Medicine, Stanford University School of Medicine, California 94305.
authors.forename: M R
authors.initials: MR
authors.lastname: Kramer
authors.forename: C
authors.initials: C
authors.lastname: Stoehr
authors.forename: N J
authors.initials: NJ
authors.lastname: Lewiston
authors.forename: V A
authors.initials: VA
authors.lastname: Starnes
authors.forename: J
authors.initials: J
authors.lastname: Theodore
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D002675:Child, Preschool; D004361:Drug Tolerance; D016041:Heart-Lung Transplantation / Q000009:adverse effects*; D006801:Humans; D007108:Immune Tolerance; D007223:Infant; D016040:Lung Transplantation / Q000009:adverse effects*; D011020:Pneumonia, Pneumocystis / Q000209:etiology / Q000517:prevention & control*; D012189:Retrospective Studies; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D000305:Adrenal Cortex Hormones; D015662:Trimethoprim, Sulfamethoxazole Drug Combination